EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical and Biological Determinants of Longitudinal Cognitive Function in Patients With GBA1 Variants and Subthalamic Deep Brain Stimulation

Moritz A Loeffler iD, Philipp Klocke, Isabel Wurster, Stefanie Lerche iD, Idil Cebi, Thomas Gasser, Alireza Gharabaghi iD, Kathrin Brockmann iD, Daniel Weiss iD

Annals of Neurology · 2026

DOI: 10.1002/ana.78139 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Neurology, 2026. Verfasst von Moritz A Loeffler und 8 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Neurology, Department of Neurodegenerative Diseases, University of Tübingen, Tübingen, Germany. Hauptthemen laut MEDLINE: Parkinson Disease, Deep Brain Stimulation, Glucosylceramidase, Cognitive Dysfunction. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Whether cognitive decline in patients with Parkinson's disease (PD) carrying GBA1 variants is accelerated after subthalamic deep brain stimulation (STN‐DBS) remains controversial. Clarifying long‐term cognitive outcomes is essential for informed decision making.

Methods

We assembled matched cohorts of patients carrying GBA1 variants with STN‐DBS (PD GBA1+DBS+ , n = 28) and without (PD G BA1+DBS− , n = 28). Additional cohorts included non‐carriers with STN‐DBS (PD GBA1−DBS+ , n = 40) and without (PD GBA1–DBS− , n = 43). Clinical, genetic, and cerebrospinal fluid (CSF) biomarkers (A β 1–42, h‐Tau, p181‐Tau, and neurofilament light chain) were analyzed. Cognition was assessed using the Montreal Cognitive Assessment (MoCA). Cognitive slopes were estimated using linear mixed models and the minimally detectable slope difference at 3‐year follow‐up was 1.33 MoCA points enabling sensitivity to clinically meaningful changes. Secondarily, conversion to dementia was analyzed with Kaplan–Meier‐analysis once the MoCA was < 21.

Results

There was no significant difference in cognitive decline between PD GBA1+DBS+ and PD GBA1+DBS− (−0.24 MoCA points/year; 95% confidence interval [CI] = –1.11 to 0.70) projecting to −0.72 MoCA points at 3‐year‐follow‐up ( p = 0.583). Secondarily, the risk for conversion to dementia did not differ between PD GBA1+DBS+ and PD GBA1+DBS− (HR = 0.55, 95% CI = 0.23–1.34, p = 0.119) or between PD GBA1−DBS+ and PD GBA1−DBS− (HR = 1.22, 95% CI = 0.53–2.83, p = 0.897). Dementia risk was associated with GBA1 status (HR = 3.04, 95% CI = 1.05–8.79, p = 0.041), baseline MoCA < 26 (HR = 3.05, 95% CI = 1.29–7.21, p = 0.011), and baseline age > 69 years (HR = 4.42, 95% CI = 1.79–10.89, p = 0.001). In GBA1 carriers, a visuospatial/executive domain score < 4/5 predicted dementia (HR = 4.71, 95% CI = 1.25–17.86, p = 0.022).

Interpretation

GBA1 variant carriers meeting general STN‐DBS indication criteria did not show accelerated cognitive decline in the presence of STN‐DBS. In addition, exploratory predictors of dementia could support counseling of DBS candidates. ANN NEUROL 2026;99:976–988

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseDeep Brain StimulationGlucosylceramidaseCognitive DysfunctionCognitionHumansMaleFemaleAgedMiddle AgedLongitudinal StudiesSubthalamic NucleusCohort StudiesBiomarkers

Substanzen

GlucosylceramidaseGBA protein, humanBiomarkers

Autor:innen und Institutionen

  • Centre for Neurology, Department of Neurodegenerative Diseases, University of Tübingen, Tübingen, Germany.
  • Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
  • Institute for Neuromodulation and Neurotechnology, University of Tübingen, Tübingen, Germany.

ORCID-Profile: Moritz A Loeffler, Stefanie Lerche, Alireza Gharabaghi, Kathrin Brockmann, Daniel Weiss

Zitieren

APA

Loeffler, M. A., Klocke, P., Wurster, I., Lerche, S., Cebi, I., Gasser, T., Gharabaghi, A., Brockmann, K., & Weiss, D. (2026). Clinical and Biological Determinants of Longitudinal Cognitive Function in Patients With GBA1 Variants and Subthalamic Deep Brain Stimulation. Annals of Neurology. https://doi.org/10.1002/ana.78139

Vancouver

Loeffler MA, Klocke P, Wurster I, Lerche S, Cebi I, Gasser T, et al. Clinical and Biological Determinants of Longitudinal Cognitive Function in Patients With GBA1 Variants and Subthalamic Deep Brain Stimulation. Annals of Neurology. 2026. doi:10.1002/ana.78139

BibTeX
@article{Loeffler2026,
  author = {Loeffler, Moritz A and Klocke, Philipp and Wurster, Isabel and Lerche, Stefanie and Cebi, Idil and Gasser, Thomas and Gharabaghi, Alireza and Brockmann, Kathrin and Weiss, Daniel},
  title = {Clinical and Biological Determinants of Longitudinal Cognitive Function in Patients With GBA1 Variants and Subthalamic Deep Brain Stimulation},
  journal = {Annals of Neurology},
  year = {2026},
  doi = {10.1002/ana.78139}
}
Kostenlos starten →